PTGX · NASDAQ · STOCK
Protagonist Therapeutics (PTGX) Stock Analysis
$143.84
52W $73.08 – $160.81
67/100
$9.24B
118.0
1.79
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is PTGX Bullish or Bearish?
Bullish.
Innellis AI committee rates Protagonist Therapeutics, Inc. (PTGX) Buy with a composite score of 67/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +7.92 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -12.08 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.67 across 3 articles, 14d) — News
Bear Case
- P/E of 113.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
67/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 0%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 113.4 is expensive by classic value standards
Growth Analyst
bullish
85
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 34.8% YoY -- genuine top-line momentum
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst
bullish
75
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
79
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.67 across 3 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 65.4 to 67.1.
- New bearish signals: 1 appeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Technical Analyst: score 48->58 (+10); +1 bullish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
59.5
Neutral
MACD Histogram
0.172
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$92.83
Resistance
$159.99
Bollinger %B
0.70
Inside Bands
Price vs Moving Averages
EMA 9
$141.14
Above
EMA 21
$142.10
Above
EMA 50
$141.07
Above
EMA 200
$116.79
Above
Fundamental Analysis
Valuation
33
Growth
89
Profitability
50
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
118.0×
P/B Ratio
11.26×
PEG Ratio
-0.14
Dividend Yield
0.00%
52W High
$160.81
52W Low
$73.08
Quality & Growth
ROE
-2117.2%
ROA
-1942.8%
Gross Margin
9985.6%
Operating Margin
2068.9%
Revenue Growth YoY
—
Debt / Equity
0.01
AI Fundamental Assessment
P/E ratio of 118.0 (rich relative to a 15-40x range); Price-to-book of 11.3x; PEG ratio of -0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -21.2%; Return on assets of -19.4%; Net margin of 29.4%; Gross margin of 99.9%; Current ratio of 21.71 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is positive (2.00); Most recent quarter beat estimates by 7.8%; 2 consecutive earnings beats; EPS growth accelerating (+107.2% -> +4480.0% QoQ); Analyst estimates rising over recent quarters
Get the Full PTGX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →